LOS ANGELES, July 24, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Zoompass Holdings, Inc. (“Zoompass” or the “Company”) (Other OTC:ZPAS) for possible violations of federal securities laws from April 24, 2017 through May 24, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired Zoompass shares during the Class Period should contact the firm prior to the July 31, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet, and until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member as well.
According to the Complaint, throughout the Class Period, Zoompass made materially false and misleading statements, and/or failed to disclose material information, specifically: that the Company unlawfully engaged in a scheme to promote the Company’s stock; that discovery of this conduct would subject the Company to heightened regulatory scrutiny and potential criminal sanctions; and that as a result, Zoompass’ public statements were materially false and misleading at all relevant times.
On May 9, 2017, the Company revealed that it had been “made aware of and requested by the OTC Markets Group, Inc. to comment on recent trading and potential promotional activity.” On May 25, 2017, Seeking Alpha published an article claiming that the Company erroneously denied that it was associated with a scheme to promote its stock; and concealed that its CEO was engaged in a purported pump-and-dump scheme. When this information reached the public, shares of Zoompass lowered in value, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FDA Approves Mitapivat for Anemia in Thalassemia Patients
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Italy Fines Apple €98.6 Million Over App Store Dominance
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



